Events

Retiro De Equipo (Recall) de Alere INRatio & INRatio2 PT/INR Monitor System. An in vitro diagnostic medical device (IVD)

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Inverness Medical Innovations Australia Pty Ltd T/A Alere.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • ID del evento
    RC-2014-RN-01289-1
  • Clase de Riesgo del Evento
    Class I
  • Fecha de inicio del evento
    2014-12-10
  • País del evento
    Australia
  • Fuente del evento
    DHTGA
  • URL de la fuente del evento
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2014-RN-01289-1
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    In certain cases an inratio & inratio2 pt/inr monitor system may provide an inr result that is clinically significantly lower than a result obtained using a reference inr system (laboratory method). this issue can arise if the patient has certain medical conditions.Br /br /further information has been published on the tga website at - http://www.Tga.Gov.Au/alert/alere-inratio-ptinr-monitor-system .
  • Acción
    Alere is advising consumers and healthcare professionals of the additional warnings and precautions required when using the INRatio & INRatio2 PT/INR Monitor systems. Consumers are requested to consult their doctor to determine if any of the following conditions apply to them: - Anaemia (haematocrit < 30%) - chronic inflammatory conditions - severe infection - advanced stage cancer or end stage renal disease - any bleeding or unusual bruising. This action has beenclosed-out on 06/07/2016.

Device

Alere INRatio & INRatio2 PT/INR Monitor System. An in vitro diagnostic medical device (IVD)
  • Modelo / Serial
    Alere INRatio & INRatio2 PT/INR Monitor System. An in vitro diagnostic medical device (IVD)INRatio Test Strips Reference Numbers: HS0100071, HS0100139, HS099007EU, HS99007G1, HS099008EU, HS99008G1Multiple Product DescriptionsARTG Number: 216755INRatio2 Monitors Reference Numbers: HS0200431, HS200433SJM, HS200433SJMK, HS0200433Multiple Product DescriptionsARTG Number: 214252
  • Clasificación del producto
    Hematology and Pathology Devices
  • Manufacturer
    Inverness Medical Innovations Australia Pty Ltd T/A Alere

Manufacturer

Inverness Medical Innovations Australia Pty Ltd T/A Alere
  • Empresa matriz del fabricante (2017)
    Abbott Laboratories
  • Comentario del fabricante
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DHTGA